medigraphic.com
ISSN 1027-2852 (Electronic)
ISSN 0864-4551 (Print)

2013, Number 2

<< Back Next >>

Biotecnol Apl 2013; 30 (2)

Proof of concept in non-human primates of the heterologous prime-boost strategy combining dengue-2 virus and recombinant proteins including domain III of the viral envelope protein

Valdés I, Hermida L, Gil L, Lazo L, Guillén G, Guzmán MG, Castro J, Romero Y, Puente P, Martín J, Marcos E, López C, Sánchez J, Niebla O, Menéndez T, Izquierdo A, Suzarte E, Silva JA

Language: English
References: 11
Page: 150-152
PDF size: 104.08 Kb.


ABSTRACT

Live attenuated viruses are the most advanced candidates against a dengue infection. They have been demonstrated to be immunogenic in preclinical and clinical studies. However, due to their replicative capacity, they require several doses to achieve the balanced immune response against the four serotypes. The use of a suitable combination using nonreplicative immunogens, without viral interference, can help to induce such a balanced response. This work dealt with the proof of concept of the heterologous prime-boost strategy combining in the same schedule in non-human primates of a live virus and the recombinant proteins containing the domain III of the viral envelope. These combinations may result in condensed immunization schedules for humans, thus reducing the number of doses with attenuated virus and the dose time spacing. In both studies, the humoral and cellular immune responses after the boost dose with each recombinant protein were evaluated. In the second study, additionally, the possibility of shortening the schedule was assessed, an advantage related with this prime-boost strategy. The boost effect was demonstrated by the neutralizing antibodies induced after recombinant protein immunizations. Additionally, it was confirmed that these neutralizing antibodies were long lasting, also the animals were able to mount a specific cellular immune response after the boost. This study won the Annual Award of the Academy of Sciences of Cuba in 2012.


REFERENCES

  1. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 2002;10(2):100-3.

  2. Kurane I. Dengue hemorrhagic fever with special emphasis on immunopathogenesis. Comp Immunol Microbiol Infect Dis. 2007;30(5-6):329-40.

  3. World Health Organization. Dengue and dengue haemorrhagic fever [Internet]. Geneva: World Health Organization; 2012 [cited 2013 Apr 17]. Available from: http:// www.who.int/mediacentre/factsheets/ fs117/en/

  4. Stephenson JR. Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ. 2005; 83(4):308-14.

  5. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, et al. Safety and immunogenicity of tetravalent liveattenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg. 2002;66(3):264-72.

  6. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in fi ve- to twelve-year-old Thai children. Pediatr Infect Dis J. 2004; 23(2):99-109.

  7. Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, Innis BL, et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in fl avivirus naive children. Am J Trop Med Hyg. 2008;78(3):426-33.

  8. Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang J, et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine. 2006; 24(9):1238-41.

  9. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in fl avivirus-naive adults. J Infect Dis. 2010; 201(3):370-7.

  10. Valdes I, Hermida L, Martin J, Menendez T, Gil L, Lazo L, et al. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. Vaccine. 2009;27(7):995-1001.

  11. Valdes I, Bernardo L, Gil L, Pavon A, Lazo L, Lopez C, et al. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology. 2009;394(2):249-58.




2020     |     www.medigraphic.com